CBLN3

Across TCGA pan-cancer cohorts, CBLN3 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated CBLN3 data layer compared with 22 for mass-spec protein.

The strongest signal is observed in breast invasive carcinoma (BRCA), where higher CBLN3 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CBLN3 expression acts as an unfavorable survival marker.

BRCA, COAD, and LIHC are the cancer types where CBLN3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BRCA	OS	Median	All	0.514	0.963	.006	8	view →
COAD	DFS	Median	All	0.160	0.693	.020	6	view →
LIHC	DFS	Median	All	0.014	0.543	<.001	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
CHOL	OS	Median	All	0.155	0.725	.029	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

CBLN3–BRCA (OS)

Open the BRCA breakdown →